Clinical Trials

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07115043 2026-03-17

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

60 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05132582 2026-03-16

HER2CLIMB-05

654 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

120 enrolled

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

416 enrolled

Triple Negative Breast Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07085767 2026-03-16

OPERA-02

1,000 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07287098 2026-03-16

preEMBER

600 enrolled

Breast Neoplasms

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT07368998 2026-03-16

optINAVO

Phase 2 Recruiting

80 enrolled

Breast Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

55 enrolled

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT06312176 2026-03-13

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06393374 2026-03-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

BreastGastrointestinalHead & Neck

Triple Negative Breast Neoplasms

NCT06681233 2026-03-13

Feasibility Study of CBCT for IGRT in Cancer Patients

Phase NA Recruiting

50 enrolled

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Urogenital Neoplasms

NCT06745804 2026-03-13

Study of 68Ga-R10602

36 enrolled

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer

NCT06841354 2026-03-13

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Phase 2 Recruiting

90 enrolled

Breast Neoplasms

NCT07261631 2026-03-13

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

BreastGastrointestinalSarcomaThoracic

180 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2 Terminated

13 enrolled 8 charts

Breast Neoplasms

NCT05382364 2026-03-12

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

25 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05417594 2026-03-12

CERTIS1

BreastCNSGastrointestinalGenitourinaryGynecologic

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06085833 2026-03-12

ANGEL

Phase NA Recruiting

2,706 enrolled

Breast Neoplasms

NCT06562192 2026-03-12

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

BreastGastrointestinalThoracic

162 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07003841 2026-03-12

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

Phase NA Recruiting

94 enrolled

Breast Neoplasms

NCT07029399 2026-03-12

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

205 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07100106 2026-03-12

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

285 enrolled

Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

Phase 2 Recruiting

125 enrolled

Breast Neoplasms

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Breast Neoplasms

NCT04572295 2026-03-11

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

51 enrolled